Last updated: 11/07/2018 11:17:26
PGx: Study of GSK2336805 in HAI115519, genotyping and phenotyping of HCV viral RNA from a Phase II study using 4 weeks of GSK2336805 in combination with pegylated interferon and ribavirin
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: PGx: Study of GSK2336805 in HAI115519, genotyping and phenotyping of HCV viral RNA from a Phase II study using 4 weeks of GSK2336805 in combination with pegylated interferon and ribavirin
Trial description: PGx: Study of GSK2336805 in HAI115519, genotyping and phenotyping of HCV viral RNA from a Phase II study using 4 weeks of GSK2336805 in combination with pegylated interferon and ribavirin
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Gardner S, Cutrell A, Elko-Simms C, Adkison K, Hamatake R, Walker J, Rodriguez-Torres M, Hong Z.A Double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.Liver Int.2014;34(6):e89-e95
Stephen Gardner, Amy Cutrell, Cindy Elko-Simms, Kimbery Adkison, Robert Hamatake, Jill Walker, Maribel Rodriguez-Torres, Zhi Hong. A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 When Given as Monotherapy and in Combination With Peginterferon alfa-2a and Ribavirin in Hepatitis C Virus Genotype 1-infected Treatment-naive Subjects. Liver Int.
Medical condition
Hepatitis C
Product
GSK2336805
Collaborators
Not applicable
Study date(s)
July 2011 to June 2012
Type
Not applicable
Phase
Not applicable
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2012-29-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website